25 stories found
Bloomberg reports that AstraZeneca, Sanofi, and Boehringer Ingelheim are investing in Owkin's AI platform to overcome bottlenecks in pharmaceutical research and rapidly generate drug candidates.
AI biotech firm Owkin has signed a collaborative agreement with pharmaceutical giant Boehringer Ingelheim to leverage machine learning for accelerating drug discovery in oncology and immunology.
The diabetes medication Jardiance has significantly boosted Boehringer Ingelheim's revenue, contributing 5.7 billion euros to the German pharmaceutical company's total sales of 15.8 billion euros.
Israeli-founded AI biotech company Immunai has launched a drug-discovery collaboration with Boehringer Ingelheim, utilizing Immunai’s single-cell AI platform to identify T-cell targets in cancer and autoimmune diseases.
Η Boehringer Ingelheim Hellas συμμετέχει και φέτος ως Χρυσός Χορηγός στην 11η εκστρατεία της ΑΜΚΕ «Με Οδηγό τον Διαβήτη», στηρίζοντας μια πρωτοβουλία που προσφέρει δωρεάν υπηρεσίες υγείας και…
A drug developed by Boehringer Ingelheim and Zealand Pharma demonstrated an average of 16.6% weight loss in patients during a late-stage clinical trial, indicating potential for obesity treatment.
A new study conducted by UNED, in collaboration with Boehringer Ingelheim, reveals that over 65% of veterinarians have considered leaving their profession due to excessive pressure. The research, released on World Veterinary Day, highlights the significant challenges faced by veterinarians.
Ensuring high-quality healthcare is crucial not only for patient well-being but also for the stable development of the economy, according to Pia Schall, General Director of Boehringer Ingelheim in Poland.
Boehringer's Hernexeos was one of the 18 drugs selected so far for the FDA Commissioner's National Priority Voucher Program that allows speedy process and cuts the review time to one to two months from the typical 10 to 12 months
Biotech company Owkin has signed a strategic agreement with pharmaceutical giant Boehringer Ingelheim to leverage artificial intelligence for accelerating the development of treatments targeting cancer and immunological diseases.
Following major investment withdrawals by companies like Eli Lilly and Boehringer Ingelheim linked to proposed healthcare reforms, the German coalition government intends to introduce measures to support the pharmaceutical industry.
The Quezon City government in the Philippines, in partnership with Boehringer Ingelheim, has initiated a citywide kidney screening and awareness program to facilitate early detection of chronic kidney disease among residents.
Monika Chapska, a Boehringer Ingelheim executive, emphasizes the importance of partnership and a long-term vision for achieving sustainable access to innovation.
Late-stage trial results for Boehringer Ingelheim's obesity drug indicate that it helps patients lose fat rather than muscle, a key finding for weight-loss treatments.
Boehringer Ingelheim announced promising study results for its weight-loss drug, Survodutid, which has increased the company's optimism for its potential market approval. This marks a significant step
Boehringer Ingelheim is expanding its investment in computational innovation by establishing a new AI Accelerator in the UK's Knowledge Quarter.
Shashank Deshpande, CEO of Boehringer Ingelheim, expresses concerns about the state of pharmaceutical research in Germany, emphasizing the need for skilled minds over rare earths, and is undeterred by Trump's pricing policies or the competitive weight-loss drug market.
Boehringer Ingelheim has partnered with artificial intelligence firm Owkin to accelerate drug discovery efforts focused on cancer and immunology. The collaboration marks another major industry move as pharmaceutical companies increasingly integrate machine learning into early-stage research.
The financial reform of statutory health insurance has been decided. Pharmaceutical companies like Boehringer Ingelheim feel betrayed. However, prices are also increasingly regulated elsewhere.
Japanese pharmaceutical company Daiichi Sankyo is increasing its investments in Germany, a move that stands in contrast to recent decisions by other major drug manufacturers like Eli Lilly and Boehringer Ingelheim to scale back their German operations.
Pharmaceutical giants Lilly and Boehringer Ingelheim have announced they are stopping millions in investments in Germany. This decision comes in response to the new GKV (Statutory Health Insurance) law.
Zealand Pharma announced that its GLP-1 drug, developed in collaboration with Boehringer Ingelheim, achieved an average of 17% weight loss in participants during a late-stage clinical trial.
Boehringer Ingelheim says pricing regime hinders access to treatments as group touts liver benefits from weight-loss drug
Pia Schall, CEO of Boehringer Ingelheim in Poland, emphasizes that high-quality healthcare and disease prevention are crucial not only for patient well-being but also for stable economic development.
Boehringer Ingelheim, recognized as a top employer, details its integrated strategy for developing and supporting a diverse workforce and creating leadership opportunities.